17 May 2013 - 17 May 2013 - US biopharmaceutical company MultiCell (OTCMKTS:MCET) said today it has filed a patent application in the US for formulations and methods for targeted delivery of its compound MCT-485 for the treatment of liver cancer.

MCT-485 is noncoding double stranded micro RNA (miRNA), which has demonstrated immune and oncolytic activity in in vitro models of hepatocellular carcinoma.

The methods and formulation for directing MCT-485 towards the tumor allow safe parenteral administration, achieve bioavailability in the tumour and contain synthetic miRNAs with immune modulating and cytotoxic effects, the company added.

MCT-485 is a cancer therapeutics based on the use of tumour necrosis factor-alpha (TLR3) antibody signalling technology, which induces tumour cell death upon direct exposure, while normal cells are affected to a minimum.